Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "SUIT-002"

From Bioblast
Line 3: Line 3:
|description=[[File:1D;2M.1;3Oct;3c;4M2;5P;6G;7S;8Gp;9U;10Rot-.png|400px]]
|description=[[File:1D;2M.1;3Oct;3c;4M2;5P;6G;7S;8Gp;9U;10Rot-.png|400px]]
|info='''A: RP2''' [[File:PDF.jpg|100px|link=http://wiki.oroboros.at/images/6/64/SUIT-002.pdf|Bioblast pdf]] »[http://wiki.oroboros.at/index.php/File:SUIT-002.pdf Versions]
|info='''A: RP2''' [[File:PDF.jpg|100px|link=http://wiki.oroboros.at/images/6/64/SUIT-002.pdf|Bioblast pdf]] »[http://wiki.oroboros.at/index.php/File:SUIT-002.pdf Versions]
}}
{{MitoPedia concepts
|mitopedia concept=SUIT protocol, SUIT A
}}
}}
::: '''[[Categories of SUIT protocols |SUIT-category]]:''' FNSGp(Oct,PGM)
::: '''[[Categories of SUIT protocols |SUIT-category]]:''' FNSGp(Oct,PGM)
::: '''[[SUIT protocol pattern]]:''' diametral 1D;2M;3Oct;4M;5P;6G;7S;8Gp;9U;10Rot;11Ama
::: '''[[SUIT protocol pattern]]:''' diametral 1D;2M;3Oct;4M;5P;6G;7S;8Gp;9U;10Rot;11Ama
__TOC__
== DLP applications ==
== DLP applications ==
::::* [[SUIT-002 O2 mt D05]]
::::* [[SUIT-002 O2 mt D05]]
Line 35: Line 34:


::::* [[SUIT-001]]
::::* [[SUIT-001]]
{{MitoPedia concepts
|mitopedia concept=SUIT protocol, SUIT A
}}

Revision as of 16:20, 11 January 2019


high-resolution terminology - matching measurements at high-resolution


SUIT-002

Description

1D;2M.1;3Oct;3c;4M2;5P;6G;7S;8Gp;9U;10Rot-.png

Abbreviation: FNSGp(Oct,PGM)

Reference: A: RP2 Bioblast pdf »Versions

SUIT-category: FNSGp(Oct,PGM)
SUIT protocol pattern: diametral 1D;2M;3Oct;4M;5P;6G;7S;8Gp;9U;10Rot;11Ama

DLP applications


References

 YearReferenceOrganismTissue;cell
MiPNet21.06 SUIT RP2018-06-25
O2k-Protocols
SUIT reference protocol for OXPHOS analysis by high-resolution respirometry.
Doerrier 2018 Methods Mol Biol2018Doerrier C, Garcia-Souza LF, Krumschnabel G, Wohlfarter Y, Mészáros AT, Gnaiger E (2018) High-Resolution FluoRespirometry and OXPHOS protocols for human cells, permeabilized fibers from small biopsies of muscle, and isolated mitochondria. Methods Mol Biol 1782:31-70. https://doi.org/10.1007/978-1-4939-7831-1_3Human
Mouse
Rat
Saccharomyces cerevisiae
Heart
Skeletal muscle
Endothelial;epithelial;mesothelial cell
Blood cells
HEK
Platelet
MitoPedia: SUIT

Steps and respiratory states

1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U;10Rot-.png

Step State Pathway Q-junction Comment - Events (E) and Marks (M)
1D REN 1D
  • ADP is added to stimulate the consumption of endogenous fuel-substrates.


2M.1 1D;2M.1
3Oct OctMP F FAO 1D;2M.1;3Oct
  • Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration.
3c OctMcP F FAO 1D;2M.1;3Oct;3c
  • Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration.
  • OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
  • Addition of cytochrome c yields a test for integrity of the mtOM (cytochrome c control efficiency). Stimulation by added cytochrome c would indicate an injury of the mtOM and limitation of respiration in the preceding state without added c due to loss of cytochrome c. Typically, cytochrome c is added immediately after the earliest ADP-activation step (OXPHOS capacity P with saturating [ADP]).
4M2 OctMP F(N) FAO 1D;2M.1;3Oct;3c;4M2
5P OctPMP FN FAO&CI 1D;2M.1;3Oct;4M2;5P
  • Respiratory stimulation by simultaneous action of the F-pathway and N-pathway with convergent electron flow in the FN-pathway for evaluation of an additive or inhibitory effect of F.
  • OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
6G OctPGMP FN FAO&CI 1D;2M.1;3Oct;4M2;5P;6G
  • Respiratory stimulation by simultaneous action of the F-pathway and N-pathway with convergent electron flow in the FN-pathway for evaluation of an additive or inhibitory effect of F.
  • OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
7S OctPGMSP FNS FAO&CI&II 1D;2M.1;3Oct;4M2;5P;6G;7S
  • Respiratory stimulation by simultaneous action of the F-pathway, N-pathway, and S-pathway, with convergent electron flow in the FNS-pathway for reconstitution of TCA cycle function and additive or inhibitory effect of F.
  • OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
8Gp OctPGMSGpP FNSGp FAO&CI&II&GpDH 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp
9U OctPGMSGpE FNSGp FAO&CI&II&GpDH 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U
10Rot SGpE SGp CII&GpDH 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U;10Rot
  • Respiratory stimulation by action of succinate and glycerophosphate, Gp, with convergent electron flow in the SGp-pathway (CII&GpDH-linked pathway to the Q-junction).
  • Noncoupled electron transfer state, ET state, with ET capacity E.
11Ama ROX 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U;10Rot;11Ama
  • Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated after addition of antimycin A (inhibitor of CIII). Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration (mt).


Questions.jpg


Click to expand or collaps


Compare SUIT protocols


MitoPedia concepts: SUIT protocol, SUIT A